Sugi Predict

Sugi Predict / Compounds / SCHEMBL10171026

SCHEMBL10171026

SCHEMBL10171026

Cn1c2ccc(B3OC(C)(C)C(C)(C)O3)cc2c(=O)c2ccc(B3OC(C)(C)C(C)(C)O3)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 1/20 0.43
▸ ATM Q13315 1/20 0.41
▸ PRMT5 O14744 2/20 0.40
▸ WDR77 Q9BQA1 2/20 0.40
▸ LPL P06858 4/20 0.38
▸ LIPG Q9Y5X9 4/20 0.38
▸ IDO1 P14902 1/20 0.37
▸ TDO2 P48775 1/20 0.37
▸ L3MBTL1 Q9Y468 5/20 0.37
▸ NPC1 O15118 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ TLR9 Q9NR96 1/20 0.36
▸ CA1 P00915 2/20 0.35
▸ CA2 P00918 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA3 P07451 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22923019 0.85 LPL (0.46) PRMT5WDR77LPLLIPGIDO1
SCHEMBL15947140 0.85 LPL (0.44) CSF1RPRMT5WDR77LPLLIPG
SCHEMBL12865914 0.81 GPR3 (0.48) ATMPRMT5WDR77LPLLIPG
SCHEMBL31153 0.78 GPR3 (0.48) PRMT5WDR77LPLLIPGL3MBTL1
SCHEMBL29704393 0.78 SMN1; SMN2 (0.43) LPLLIPGL3MBTL1IRAK4MEN1
SCHEMBL15331596 0.78 SMN1; SMN2 (0.43) LPLLIPGL3MBTL1IRAK4MEN1
SCHEMBL16291887 0.78 NQO2 (0.49) CSF1RPRMT5WDR77LPLLIPG
SCHEMBL13832961 0.76 LPL (0.42) CSF1RATMPRMT5WDR77LPL
SCHEMBL29547675 0.76 IRAK4 (0.40) CSF1RPRMT5WDR77LPLLIPG
SCHEMBL20120904 0.76 IRAK4 (0.40) CSF1RPRMT5WDR77LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150554-B2 Fused ring inhibitors of hepatitis C PRESIDIO PHARMACEUTICALS, INC. (US) 2015-10-06 — — US disclosed
US-9150554-B2 Fused ring inhibitors of hepatitis C PRESIDIO PHARMACEUTICALS, INC. (US) 2015-10-06 — — US disclosed
US-8999967-B2 Tricyclic fused ring inhibitors of hepatitis C PRESIDIO PHARMACEUTICALS, INC. (US) 2015-04-07 — — US disclosed
US-8999967-B2 Tricyclic fused ring inhibitors of hepatitis C PRESIDIO PHARMACEUTICALS, INC. (US) 2015-04-07 — — US disclosed
US-20130296304-A1 TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-07 — — US disclosed
US-20130296304-A1 TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-07 — — US disclosed
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-16 — — US disclosed
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296304-A1 TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C HAVCR2, HCCS, LIPC CSF1R 3732/4885ATM 4135/4885PRMT5 3561/4885
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C HAVCR2, HCCS, ZC3HAV1 CSF1R 3716/4885ATM 3917/4885PRMT5 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.